<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805817</url>
  </required_header>
  <id_info>
    <org_study_id>cuzuncakmak1907</org_study_id>
    <nct_id>NCT01805817</nct_id>
  </id_info>
  <brief_title>Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality</brief_title>
  <official_title>Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral combined contraceptives(OC) have both progesterone and estrogen inside.
      Levonorgestrel-releasing intrauterine device(LNG_IUS) has only progestagen.

      Copper IUD does not have any hormonal molecule inside.

        -  Hypothesis is OC has more systemic beneficial or side effects than LNG_IUS or copper
           IUD. LNG_IUS has more local effects than copper IUD.

        -  Study reflects the beneficial or side effects of estrogen+progestagen pills and only
           progestogen inside device.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipid profile (HDL,VLDL,IDL,LDL,Lp(a),VLDL)Lng-ius users, Copper-iud users and combined oral contraceptive users (composite measurement)</measure>
    <time_frame>Change from Baseline HDL,Very-low-density lipoprotein (VLDL),IDL,Low-density lipoprotein (LDL),Lp(a),VLDL concentrations at 3 months; Baseline to 6 months, Baseline to 12 months of outcome will have assessed</time_frame>
    <description>60 lng-ius users, 60 Copper iud users and 60 combined oral contraceptive users will compared with total lipoprotein, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), lipoprotein(a) (Lp(a)), intermediate-density lipoprotein (IDL ), HDL subclasses , LDL subclasses , VLDL subclasses ,values at 3-6-12 months follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>coagulation parameters(composite measurement)</measure>
    <time_frame>Change from Baseline aPTT, prothrombin time, INR, D-dimer,factor VIII, fibrinogen, platelet counts values at 3 months; Baseline to 6 months, Baseline to 12 months of outcome will have assessed</time_frame>
    <description>60 lng-ius users, 60 Copper iud users and 60 combined oral contraceptive users will compared with activated partial thromboplastin time (aPTT), prothrombin time, international normalized ratio(INR), D-dimer,factor VIII, fibrinogen, platelet counts values with each other at 3-6-12 months follow up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>menstrual pattern and bleeding scores(composite measurement)</measure>
    <time_frame>Change from Baseline pictorial blood scoring system scores at 3 months, Baseline to 6 months, Baseline to 12 months will be assessed</time_frame>
    <description>60 lng-ius users, 60 Copper iud users and 60 combined oral contraceptive users menstrual pattern will be recorded and menstrual bleeding scores will be measured by pictorial blood scoring system and it will be compared with each other at 3-6-12 months follow up.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Contraceptive Methods Comparison</condition>
  <arm_group>
    <arm_group_label>Levonorgestrel releasing intrauterine device, contraception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNG-IUS - Mirena ®,20μgr, once intrauterine insertion per 5 year, 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YASMIN® (Drospirenone/Ethinyl Estradiol), contraception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral, once a day, 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Copper T 380 A , contraception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intrauterine device, once per 10 year, 1 year period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YASMIN® (Drospirenone/Ethinyl Estradiol)</intervention_name>
    <description>oral contraceptive pills</description>
    <arm_group_label>Levonorgestrel releasing intrauterine device, contraception</arm_group_label>
    <arm_group_label>YASMIN® (Drospirenone/Ethinyl Estradiol), contraception</arm_group_label>
    <arm_group_label>Copper T 380 A , contraception</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Copper-T is an intrauterine device (IUD)</intervention_name>
    <description>intrauterine device for contraception</description>
    <arm_group_label>Levonorgestrel releasing intrauterine device, contraception</arm_group_label>
    <arm_group_label>YASMIN® (Drospirenone/Ethinyl Estradiol), contraception</arm_group_label>
    <arm_group_label>Copper T 380 A , contraception</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>levonorgestrel-releasing system</intervention_name>
    <description>intrauterine device</description>
    <arm_group_label>Levonorgestrel releasing intrauterine device, contraception</arm_group_label>
    <arm_group_label>YASMIN® (Drospirenone/Ethinyl Estradiol), contraception</arm_group_label>
    <arm_group_label>Copper T 380 A , contraception</arm_group_label>
    <other_name>Miirena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women who desire contraception

        Exclusion Criteria:

          -  Women with large fibroids,abnormal uterine bleeding including heavy menstrual bleeding
             or using any contraceptive pills during the previous 3 months were excluded from the
             study. Other exclusion criteria were pelvic inflammatory disease, pregnancy, genital
             tumor or thromboembolic disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cihangir Uzunçakmak, M.D.</last_name>
    <phone>0090 505 4505808</phone>
    <email>cuzuncakmak@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istanbul Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cihangir Uzunçakmak, M.D.</last_name>
      <phone>0090 505 4505808</phone>
      <email>cuzuncakmak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Cihangir Uzuncakmak, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=lng+ius+combined+oral+contraceptives</url>
    <description>database for medical publication</description>
  </link>
  <reference>
    <citation>Haliloglu B, Celik A, Ilter E, Bozkurt S, Ozekici U. Comparison of uterine artery blood flow with levonorgestrel intrauterine system and copper intrauterine device. Contraception. 2011 Jun;83(6):578-81. doi: 10.1016/j.contraception.2010.09.001. Epub 2010 Oct 18.</citation>
    <PMID>21570557</PMID>
  </reference>
  <reference>
    <citation>Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011 Feb;112(2):126-30. doi: 10.1016/j.ijgo.2010.08.009. Epub 2010 Nov 19.</citation>
    <PMID>21092958</PMID>
  </reference>
  <reference>
    <citation>Mansour D, Gemzell-Danielsson K, Inki P, Jensen JT. Fertility after discontinuation of contraception: a comprehensive review of the literature. Contraception. 2011 Nov;84(5):465-77. doi: 10.1016/j.contraception.2011.04.002. Epub 2011 Jun 8. Review.</citation>
    <PMID>22018120</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Cihangir Uzunçakmak</investigator_full_name>
    <investigator_title>Medical Doctor, OB/GYN</investigator_title>
  </responsible_party>
  <keyword>lipid profile</keyword>
  <keyword>bleeding scores</keyword>
  <keyword>menstrual pattern</keyword>
  <keyword>beneficial</keyword>
  <keyword>side effects</keyword>
  <keyword>changes in a year period</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

